Cargando…
Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
BACKGROUND: Aptamer has been called “chemical antibody” which displays the specific affinity to target molecules compared to that of antibodies and possesses several therapeutic advantages over antibodies in terms of size, accessibility to synthesis, and modification. Based on the attractive propert...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613924/ https://www.ncbi.nlm.nih.gov/pubmed/34823601 http://dx.doi.org/10.1186/s40824-021-00244-4 |